Corporate Information And Statement Of Ifrs Compliance [Abstract]
| Concept |
2022-01-01 to 2022-12-31 |
As at 2022-12-31 |
As at 2021-12-31 |
|---|---|---|---|
| Corporate information and statement of IFRS compliance [abstract] | |||
| Name of reporting entity or other means of identification |
BerGenBio ASA
|
— | — |
| Domicile of entity |
Norway
|
— | — |
| Legal form of entity |
public limited liability
|
— | — |
| Country of incorporation |
Norway
|
— | — |
| Address of entity's registered office |
Møllendalsbakken 9, 5009
|
— | — |
| Principal place of business |
Norway
|
— | — |
| Description of nature of entity's operations and principal activities |
clinical-stage biopharmaceutical company developing
|
— | — |
| Name of parent entity |
BerGenBio ASA
|
— | — |
| Disclosure of amounts to be recovered or settled after twelve months for classes of assets and liabilities that contain amounts to be recovered or settled both no more and more than twelve months after reporting date [text block] | — | — | — |
| Disclosure of amounts to be recovered or settled after twelve months for classes of assets and liabilities that contain amounts to be recovered or settled both no more and more than twelve months after reporting date [abstract] | |||
| Disclosure of amounts to be recovered or settled after twelve months for classes of assets and liabilities that contain amounts to be recovered or settled both no more and more than twelve months after reporting date [line items] | |||
| Current trade payables | — |
29,634,000
NOK
|
26,726,000
NOK
|
| Disclosure of objectives, policies and processes for managing capital [text block] |
|
— | — |